Catherine Skari

Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19

The two companies will jointly develop, manufacture and distribute AT-527, Atea’s investigational oral antiviral for the potential treatment of COVID-19.…

Read More »

Leave No Patient Behind: A TIF Declaration For Access To Health At The Time of The COVID-19 Pandemic

Download the TIF Declaration HERE

Read More »

Why We Need to Talk about Depression and Thalassaemia by Roanna Maharaj

Read More »

What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?

There is a lot of hustle and bustle in the scientific fields of thalassemia and sickle cell disease during the…

Read More »

Virtual Delegation Visit to Serbia – 23-24 October 2020

Read More »

TIF Participates in EMA’s Annual Training Day 2020

TIF has participated in the Annual Training Day of the European Medicines Agency (EMA), held on 23 October 2020. TIF…

Read More »

EU Approves Adakveo to Treat Vaso Occlusive Crises in Sickle Cell Disease Patients

The European Commission has approved Novartis’ Adakveo (crizanlizumab) as a preventive treatment for recurrent Vaso-Occlusive Crises (VOCs) in patients, 16 and older, with sickle cell…

Read More »

TIF At The 6th Annual CEETII Patient Advocacy Group Forum 2020

Read More »

THAL e-COURSE: Blood Transfusion in Thalassaemia by Prof. Constantina Politis

Read More »